FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2779371672> ?p ?o ?g. }

• W2779371672 endingPage "216" @default.
• W2779371672 startingPage "205" @default.
• W2779371672 abstract "Objectives To examine the knowledge, attitudes, and interest of an inner‐city population toward pharmacogenetic testing, with the primary objective of identifying facilitators and barriers toward pharmacogenetic testing; and secondary objectives of determining predictors of patient interest in pharmacogenetic testing and how much patients would pay for the test. Methods Patients were recruited from an Antithrombosis Clinic from March to April 2014. A cross‐sectional 19‐question survey was administered in person to determine patients' knowledge and awareness of pharmacogenetic testing and collect demographic information. After explaining pharmacogenetics, patients ranked their interest toward the test and answered open‐ended questions that elicited facilitators and barriers toward pharmacogenetic testing and elucidated how much patients would pay for testing. Results A total of 120 patients (mean age 55.0 ± 14.0 years, 39.2% male, 69.2% African American) were surveyed. Facilitators included providing further information about pharmacogenetic testing; elaborating on benefits of testing to predict treatment efficacy; patients' trust in their providers to make correct genotype‐guided prescribing decisions; and insurance coverage and test affordability. Barriers to testing included concerns about the negative consequences associated with test results; burden of the testing process; perceived lack of utility among elderly and those whose medications were working; privacy issues; and concerns regarding insurance coverage and test affordability. Women had 4.2 times higher adjusted odds of being interested in pharmacogenetic testing. Almost half (44.4%) of the patients with high interest in the test were willing to pay $20 or more, whereas 76.2% of patients with low interest wanted testing at no cost. Conclusion This study identified facilitators, such as providing additional pharmacogenetic test information, and barriers, such as perceived negative impact of the results and test utility, as issues to address when engaging an urban, largely minority population in pharmacogenetic testing. Female sex was a predictor of interest toward pharmacogenetic testing. These facilitators and barriers should be taken into consideration as pharmacogenetic testing gains widespread utility among inner‐city populations." @default.
• W2779371672 created "2018-01-05" @default.
• W2779371672 creator A5032740060 @default.
• W2779371672 creator A5067905920 @default.
• W2779371672 creator A5070710719 @default.
• W2779371672 creator A5084577356 @default.
• W2779371672 date "2018-01-21" @default.
• W2779371672 modified "2023-10-16" @default.
• W2779371672 title "Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population" @default.
• W2779371672 cites W1967966328 @default.
• W2779371672 cites W1969692023 @default.
• W2779371672 cites W1978282854 @default.
• W2779371672 cites W1985430617 @default.
• W2779371672 cites W1991760929 @default.
• W2779371672 cites W2000445173 @default.
• W2779371672 cites W2005333466 @default.
• W2779371672 cites W2033812048 @default.
• W2779371672 cites W2041212611 @default.
• W2779371672 cites W2043462668 @default.
• W2779371672 cites W2048092546 @default.
• W2779371672 cites W2060858218 @default.
• W2779371672 cites W2063752993 @default.
• W2779371672 cites W2076861819 @default.
• W2779371672 cites W2083979572 @default.
• W2779371672 cites W2091338183 @default.
• W2779371672 cites W2112250282 @default.
• W2779371672 cites W2128189669 @default.
• W2779371672 cites W2132146462 @default.
• W2779371672 cites W2150104072 @default.
• W2779371672 cites W2150609677 @default.
• W2779371672 cites W2153848373 @default.
• W2779371672 cites W2161809150 @default.
• W2779371672 cites W2164684297 @default.
• W2779371672 cites W2168141575 @default.
• W2779371672 cites W2325433754 @default.
• W2779371672 cites W2331439827 @default.
• W2779371672 cites W2550880461 @default.
• W2779371672 cites W2588108371 @default.
• W2779371672 cites W2597078841 @default.
• W2779371672 doi "https://doi.org/10.1002/phar.2077" @default.
• W2779371672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29286540" @default.
• W2779371672 hasPublicationYear "2018" @default.
• W2779371672 type Work @default.
• W2779371672 sameAs 2779371672 @default.
• W2779371672 citedByCount "19" @default.
• W2779371672 countsByYear W27793716722019 @default.
• W2779371672 countsByYear W27793716722020 @default.
• W2779371672 countsByYear W27793716722021 @default.
• W2779371672 countsByYear W27793716722022 @default.
• W2779371672 countsByYear W27793716722023 @default.
• W2779371672 crossrefType "journal-article" @default.
• W2779371672 hasAuthorship W2779371672A5032740060 @default.
• W2779371672 hasAuthorship W2779371672A5067905920 @default.
• W2779371672 hasAuthorship W2779371672A5070710719 @default.
• W2779371672 hasAuthorship W2779371672A5084577356 @default.
• W2779371672 hasConcept C104317684 @default.
• W2779371672 hasConcept C126322002 @default.
• W2779371672 hasConcept C135763542 @default.
• W2779371672 hasConcept C143095724 @default.
• W2779371672 hasConcept C151730666 @default.
• W2779371672 hasConcept C151956035 @default.
• W2779371672 hasConcept C185592680 @default.
• W2779371672 hasConcept C2777267654 @default.
• W2779371672 hasConcept C2780673598 @default.
• W2779371672 hasConcept C2908647359 @default.
• W2779371672 hasConcept C512399662 @default.
• W2779371672 hasConcept C55493867 @default.
• W2779371672 hasConcept C55775858 @default.
• W2779371672 hasConcept C71924100 @default.
• W2779371672 hasConcept C86803240 @default.
• W2779371672 hasConcept C99454951 @default.
• W2779371672 hasConceptScore W2779371672C104317684 @default.
• W2779371672 hasConceptScore W2779371672C126322002 @default.
• W2779371672 hasConceptScore W2779371672C135763542 @default.
• W2779371672 hasConceptScore W2779371672C143095724 @default.
• W2779371672 hasConceptScore W2779371672C151730666 @default.
• W2779371672 hasConceptScore W2779371672C151956035 @default.
• W2779371672 hasConceptScore W2779371672C185592680 @default.
• W2779371672 hasConceptScore W2779371672C2777267654 @default.
• W2779371672 hasConceptScore W2779371672C2780673598 @default.
• W2779371672 hasConceptScore W2779371672C2908647359 @default.
• W2779371672 hasConceptScore W2779371672C512399662 @default.
• W2779371672 hasConceptScore W2779371672C55493867 @default.
• W2779371672 hasConceptScore W2779371672C55775858 @default.
• W2779371672 hasConceptScore W2779371672C71924100 @default.
• W2779371672 hasConceptScore W2779371672C86803240 @default.
• W2779371672 hasConceptScore W2779371672C99454951 @default.
• W2779371672 hasFunder F4320332161 @default.
• W2779371672 hasFunder F4320337534 @default.
• W2779371672 hasIssue "2" @default.
• W2779371672 hasLocation W27793716721 @default.
• W2779371672 hasLocation W27793716722 @default.
• W2779371672 hasOpenAccess W2779371672 @default.
• W2779371672 hasPrimaryLocation W27793716721 @default.
• W2779371672 hasRelatedWork W1977975764 @default.
• W2779371672 hasRelatedWork W2022218623 @default.
• W2779371672 hasRelatedWork W2044167227 @default.
• W2779371672 hasRelatedWork W2057889029 @default.

• next